News
During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...
RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...
Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...
Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...
Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.
Chimeric antigen receptor (CAR) T-cell immunotherapy was reported by ASCO in 2018 as the advance of the year. This innovative cancer treatment originated from intensive experimental work in academic ...
The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...
In a new innovative and groundbreaking medical achievement, Abu Dhabi Stem Cells Centre (ADSCC) has manufactured the UAE's ...
Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...
The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results